Rheumatoid Arthritis: Update Bulletin #3 - ResearchAndMarkets.com

DUBLIN--()--The "Rheumatoid Arthritis: Update Bulletin #3" newsletter has been added to ResearchAndMarkets.com's offering.

Business Questions

  • How do KOLs perceive Boehringer Ingelheim's adalimumab biosimilar, Cyltezo?
  • With three adalimumab biosimilars now approved in Europe, what concerns do prescribers have with regard to multiple biosimilar versions becoming available?
  • How do KOLs view Sandoz's Rixathon, the second rituximab biosimilar to enter the RA space in Europe?
  • Celltrion is currently developing a subcutaneously administered infliximab biosimilar, but what need is there currently for a subcutaneous version of this product?
  • What concerns might prescribers have regarding Celltrion's subcutaneous infliximab biosimilar?

For more information about this newsletter visit https://www.researchandmarkets.com/research/23smds/rheumatoid?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Allergy and Immunology

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Allergy and Immunology